<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Placed-on-Calendar-Senate" dms-id="HCE82150A266743E9A9511263283CF498" public-private="public" key="G" bill-type="olc" stage-count="1"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>115 HR 1418 PCS: Animal Drug and Animal Generic Drug User Fee Amendments of 2023</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date></dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">II</distribution-code><calendar>Calendar No. 210</calendar><congress display="yes">118th CONGRESS</congress><session display="yes">1st Session</session><legis-num display="yes">H. R. 1418</legis-num><current-chamber>IN THE SENATE OF THE UNITED STATES</current-chamber><action><action-date>July 18, 2023</action-date><action-desc>Received</action-desc></action><action><action-date>September 20, 2023</action-date><action-desc>Read twice and placed on the calendar</action-desc></action><legis-type>AN ACT</legis-type><official-title display="yes">To amend the Federal Food, Drug, and Cosmetic Act to reauthorize user fee programs relating to new animal drugs and generic new animal drugs.</official-title></form><legis-body display-enacting-clause="yes-display-enacting-clause" style="OLC" id="HEEE0D47BE02F4B20B47A1C4A725E2C18"><section id="HCA9A06A8558C48B4BEBC9D265BD36745" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Animal Drug and Animal Generic Drug User Fee Amendments of 2023</short-title></quote>. </text></section><section id="H35B57914FC344603A3D92D897AB578F4"><enum>2.</enum><header>Table of contents</header><text display-inline="no-display-inline">The table of contents for this Act is the following: </text><toc container-level="legis-body-container" quoted-block="no-quoted-block" lowest-level="section" regeneration="yes-regeneration" lowest-bolded-level="division-lowest-bolded"><toc-entry idref="HCA9A06A8558C48B4BEBC9D265BD36745" level="section">Sec. 1. Short title.</toc-entry><toc-entry idref="H35B57914FC344603A3D92D897AB578F4" level="section">Sec. 2. Table of contents.</toc-entry><toc-entry idref="HC4EF9F67278B465DB14CB583FA1F0641" level="title">Title I—Fees Relating to Animal Drugs</toc-entry><toc-entry idref="H73CBC7AD785D4551AF412CD2A877DB47" level="section">Sec. 101. Short title; finding.</toc-entry><toc-entry idref="H6DA7C91CD9D64478947F1882015BBC01" level="section">Sec. 102. Definitions.</toc-entry><toc-entry idref="H33F204F61C094D8A853A1328A8AECD56" level="section">Sec. 103. Authority to assess and use animal drug fees.</toc-entry><toc-entry idref="HC11CA5D390A9483A9B91F963028D3A1B" level="section">Sec. 104. Reauthorization; reporting requirements.</toc-entry><toc-entry idref="HCF74E576ECBE4EE58A5E9D7B2CD34772" level="section">Sec. 105. Savings clause.</toc-entry><toc-entry idref="H05348EF5DEFB4E0880EF39F3A55DE111" level="section">Sec. 106. Effective date.</toc-entry><toc-entry idref="H81D18433033948A2967F7FB86988C157" level="section">Sec. 107. Sunset dates.</toc-entry><toc-entry idref="H1DCACC2CFAB64FB8943A6A41CCEFEA6D" level="title">Title II—Fees Relating to Generic Animal Drugs</toc-entry><toc-entry idref="HCA9A0A77A8FF48808C7FE6F06E7C3379" level="section">Sec. 201. Short title; finding.</toc-entry><toc-entry idref="H757D356F8C0043D3A6BC215526304001" level="section">Sec. 202. Authority to assess and use generic new animal drug fees.</toc-entry><toc-entry idref="H2E56B76819BA436BBD1F2F2419B9503B" level="section">Sec. 203. Reauthorization; reporting requirements.</toc-entry><toc-entry idref="H1A76396576CD44CBA23BB789D7AA4F63" level="section">Sec. 204. Savings clause.</toc-entry><toc-entry idref="H2B1DE415AAE543748C10DC0CF5BE0486" level="section">Sec. 205. Effective date.</toc-entry><toc-entry idref="HAF76775DBD9845738378B6233DBDB3C2" level="section">Sec. 206. Sunset dates.</toc-entry><toc-entry idref="HEC290649D102411FAE4C60904BFF0A31" level="title">Title III—Supporting Animal and Human Health</toc-entry><toc-entry idref="H789C154723164760A9706AE0BAEC21C8" level="section">Sec. 301. Reporting requirements.</toc-entry><toc-entry idref="H850F4732AEBF43B8B53D72ED2EAC3401" level="section">Sec. 302. Definition of major species.</toc-entry><toc-entry idref="H2F4EC2C7237A4E80A1463C864D8F4753" level="section">Sec. 303. Antimicrobial resistance.</toc-entry></toc></section><title id="HC4EF9F67278B465DB14CB583FA1F0641" style="OLC"><enum>I</enum><header>Fees Relating to Animal Drugs</header><section id="H73CBC7AD785D4551AF412CD2A877DB47"><enum>101.</enum><header>Short title; finding</header><subsection id="H8DB50F681352464891ED66AE2CBD1802"><enum>(a)</enum><header>Short title</header><text display-inline="yes-display-inline">This title may be cited as the <quote><short-title>Animal Drug User Fee Amendments of 2023</short-title></quote>.</text></subsection><subsection id="H9A1B4E6597A24B50B03777F6B0EA699C"><enum>(b)</enum><header>Finding</header><text display-inline="yes-display-inline">Congress finds that the fees authorized by the amendments made in this title will be dedicated toward expediting the animal drug development process and the review of new and supplemental animal drug applications and investigational animal drug submissions as set forth in the goals identified for purposes of part 4 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-11">21 U.S.C. 379j–11 et seq.</external-xref>), in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Energy and Commerce of the House of Representatives and the Chairman of the Committee on Health, Education, Labor, and Pensions of the Senate as set forth in the Congressional Record.</text></subsection></section><section id="H6DA7C91CD9D64478947F1882015BBC01"><enum>102.</enum><header>Definitions</header><text display-inline="no-display-inline">Section 739 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-11">21 U.S.C. 379j–11</external-xref>) is amended—</text><paragraph id="H70A09FCC21F9434B91C0E3F2511830C7"><enum>(1)</enum><text>in paragraph (3), by striking <quote>national drug code</quote> and inserting <quote>National Drug Code</quote>; and </text></paragraph><paragraph id="H5AD69575A42246F9BABDDA76334FC53F"><enum>(2)</enum><text display-inline="yes-display-inline">by amending paragraph (8)(I) to read as follows:</text><quoted-block style="OLC" id="H6B5C6CE0D5E04191AF57303B05DFEE5D" display-inline="no-display-inline"><subparagraph id="HA33C14D93CDE4EDAACA96CC38C8B3ACF"><enum>(I)</enum><text display-inline="yes-display-inline">The activities necessary for implementation of the United States and European Union Mutual Recognition Agreement for Pharmaceutical Good Manufacturing Practice Inspections, and the United States and United Kingdom Mutual Recognition Agreement Sectoral Annex for Pharmaceutical Good Manufacturing Practices, and other mutual recognition agreements, with respect to animal drug products subject to review, including implementation activities prior to and following product approval.</text></subparagraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></section><section id="H33F204F61C094D8A853A1328A8AECD56"><enum>103.</enum><header>Authority to assess and use animal drug fees</header><subsection commented="no" id="H23AA54446A1F49E4B8CA8C9BFD5293D7"><enum>(a)</enum><header>In general</header><text display-inline="yes-display-inline">Section 740(a)(1)(A)(ii) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-12">21 U.S.C. 379j–12(a)(1)(A)(ii)</external-xref>) is amended—</text><paragraph id="H097A769C5C1341389D55B3266617B6BF"><enum>(1)</enum><text>in subclause (I), by striking <quote>and</quote> at the end;</text></paragraph><paragraph id="H3C6D6FFCEDD941E8B5A7486DFF250DD7"><enum>(2)</enum><text>in subclause (II), by striking the period at the end and inserting <quote>; and</quote>; and</text></paragraph><paragraph id="HA48FE7F70CD243018DA09D3E0BDB4344"><enum>(3)</enum><text>by adding at the end the following: </text><quoted-block style="OLC" id="HB9A7CC2341B4464F9CD084258B910D3F" display-inline="no-display-inline"><subclause id="H542F859E541D435F996A77511473D6F9"><enum>(III)</enum><text display-inline="yes-display-inline">an application for conditional approval under section 571 of a new animal drug for which an animal drug application submitted under section 512(b)(1) has been previously approved under section 512(d)(1) for another intended use.</text></subclause><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="HB7E82077355448439E644B632B57F6A8"><enum>(b)</enum><header>Fee revenue amounts</header><text display-inline="yes-display-inline">Section 740(b)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-12">21 U.S.C. 379j–12(b)(1)</external-xref>) is amended to read as follows:</text><quoted-block style="OLC" id="H7480AEE2016F477E971A13860AD56912" display-inline="no-display-inline"><paragraph id="HC0A7151BF1254A4A8D03508ECCBA9F6A"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Subject to subsections (c), (d), (f), and (g), for each of fiscal years 2024 through 2028, the fees required under subsection (a) shall be established to generate a total revenue amount of $33,500,000.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection commented="no" id="HB65C2BC24D914A46870962799EF98D46"><enum>(c)</enum><header>Annual fee setting; adjustments</header><paragraph commented="no" id="H1A34E8BB94EF4FACA6B4EFB8C4E8E498"><enum>(1)</enum><header>Annual fee setting</header><text display-inline="yes-display-inline">Section 740(c)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-12">21 U.S.C. 379j–12(c)(1)</external-xref>) is amended to read as follows:</text><quoted-block style="OLC" id="HB8DC81312BA04127AF78805E9A483E67" display-inline="no-display-inline"><paragraph id="HE331353084494D26BC38D907AB9AE3E4"><enum>(1)</enum><header>Annual fee setting</header><text display-inline="yes-display-inline">Not later than 60 days before the start of each fiscal year beginning after September 30, 2023, the Secretary shall—</text><subparagraph id="H70354EFD7F3543BFBF2809E306A125FA"><enum>(A)</enum><text display-inline="yes-display-inline">establish for that fiscal year animal drug application fees, supplemental animal drug application fees, animal drug sponsor fees, animal drug establishment fees, and animal drug product fees based on the revenue amounts established under subsection (b) and the adjustments provided under this subsection; and</text></subparagraph><subparagraph id="H6C2C02EB6FFD413A911917027BC15C93"><enum>(B)</enum><text display-inline="yes-display-inline">publish such fee revenue amounts and fees in the Federal Register.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph><paragraph id="H34AE025FB63D44458D0B01E4A9F5CD2F"><enum>(2)</enum><header>Inflation adjustment</header><text display-inline="yes-display-inline">Section 740(c)(2) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-12">21 U.S.C. 379j–12(c)(2)</external-xref>) is amended—</text><subparagraph id="H3EABC31D50724F3CA073E54B7E278A5C"><enum>(A)</enum><text>in subparagraph (A)—</text><clause id="H51FE1E93E0F44564A1BAA05B9B833481"><enum>(i)</enum><text>in the matter preceding clause (i), by striking <quote>2020</quote> and inserting <quote>2025</quote>; and</text></clause><clause id="H274074E9B1334308A4BDFDB08B226751"><enum>(ii)</enum><text>in clause (iii), by striking <quote>Baltimore</quote> and inserting <quote>Arlington-Alexandria</quote>; and</text></clause></subparagraph><subparagraph id="H64C54EF64F5A4DBDA439AAC31DAC32FA"><enum>(B)</enum><text display-inline="yes-display-inline">in subparagraph (B), by striking <quote>2020</quote> and inserting <quote>2025</quote>.</text></subparagraph></paragraph><paragraph id="H37CFF8A8CEF04EFC889BD58E95824FC9"><enum>(3)</enum><header>Workload adjustments</header><text display-inline="yes-display-inline">Section 740(c)(3) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-12">21 U.S.C. 379j–12(c)(3)</external-xref>) is amended—</text><subparagraph id="HBBF51CA60C0943EB86B7E58E216A8912"><enum>(A)</enum><text display-inline="yes-display-inline">in subparagraph (A)—</text><clause id="H896F41D668D74C2EBAB3894DC1498450"><enum>(i)</enum><text>in the matter preceding clause (i)—</text><subclause id="H9496AF1F954D4AAFBFEA9A5FFF3276B6"><enum>(I)</enum><text>by striking <quote>2020</quote> and inserting <quote>2025</quote>; and</text></subclause><subclause id="HE864133AE3E548EB832693DC6D47535A"><enum>(II)</enum><text>by striking <quote>subparagraphs (B) and (C)</quote> and inserting <quote>subparagraph (B)</quote>;</text></subclause></clause><clause id="H3C0E1A54799B4A2EA0A62C2B95761CE1"><enum>(ii)</enum><text>in clause (i) by striking <quote>and</quote> at the end; and</text></clause><clause id="H6DB379839B82412CAE8AF80BFEDC20F1"><enum>(iii)</enum><text>by striking clause (ii) and inserting the following: </text><quoted-block style="OLC" id="HD4D6AC86E92549EC9C44E0E4494B0146" display-inline="no-display-inline"><clause id="H3F7FFBAF2E9545C8967E83CF3B37BF07"><enum>(ii)</enum><text display-inline="yes-display-inline">such adjustment shall be made for each fiscal year that the adjustment determined by the Secretary is greater than 3 percent, except for the first fiscal year that the adjustment is greater than 3 percent; and</text></clause><clause id="H38D32E99425749C1A3712E3B7EED1F43"><enum>(iii)</enum><text display-inline="yes-display-inline">the Secretary shall publish in the Federal Register notice under paragraph (1) the amount of such adjustment and the supporting methodologies.</text></clause><after-quoted-block>;</after-quoted-block></quoted-block></clause></subparagraph><subparagraph id="H7D26B331DDC541E8BA91A4687A097F88"><enum>(B)</enum><text>by striking subparagraph (B); and</text></subparagraph><subparagraph id="H16A7BA5F3CE04FA297E4795185A84E80"><enum>(C)</enum><text>by redesignating subparagraph (C) as subparagraph (B). </text></subparagraph></paragraph><paragraph id="H4F26BFE1FC714619B20DA4A304649279" commented="no"><enum>(4)</enum><header>Final year adjustment</header><text display-inline="yes-display-inline">Section 740(c)(4) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-12">21 U.S.C. 379j–12(c)(4)</external-xref>) is amended to read as follows: </text><quoted-block style="OLC" id="HBB2948A529E84992BBFE8EFF3EC7565A" display-inline="no-display-inline"><paragraph id="H9FF02A4F398D4C1ABB5B51A0A5A90C65" commented="no"><enum>(4)</enum><header><italic></italic>Operating reserve adjustment</header><subparagraph id="H055452E6B5084E0FAB15A0ADF6C7A3A9" commented="no"><enum>(A)</enum><header>In general</header><text display-inline="yes-display-inline">For fiscal year 2025 and each subsequent fiscal year, after the fee revenue amount established under subsection (b) is adjusted in accordance with paragraphs (2) and (3), the Secretary shall—</text><clause id="H13EEC28C1E244DFBA29A5E08E14EA7C3" commented="no"><enum>(i)</enum><text display-inline="yes-display-inline">increase the fee revenue amount for such fiscal year, if necessary to provide an operating reserve of not less than 12 weeks; or</text></clause><clause id="H4F0E3006BA4F49E7B964035034EA89E5" commented="no"><enum>(ii)</enum><text display-inline="yes-display-inline">if the Secretary has an operating reserve in excess of the number of weeks specified in subparagraph (C) for that fiscal year, the Secretary shall decrease the fee revenue amount to provide not more than the number of weeks specified in subparagraph (C) for that fiscal year.</text></clause></subparagraph><subparagraph id="H9FD3BA067A1048CFBA5B430E827B56B9" commented="no"><enum>(B)</enum><header>Carryover user fees</header><text display-inline="yes-display-inline">For purposes of this paragraph, the operating reserve of carryover user fees for the process for the review of animal drug applications does not include carryover user fees that have not been appropriated.</text></subparagraph><subparagraph id="HF78437E237084E36ADBA9EABD23FF553" commented="no"><enum>(C)</enum><header>Number of weeks of operating reserves</header><text>The number of weeks of operating reserves specified in this subparagraph is—</text><clause id="H5C410458514F4E1D94C4DEA77AF5FD48" commented="no"><enum>(i)</enum><text display-inline="yes-display-inline">22 weeks for fiscal year 2025;</text></clause><clause id="H5FE365C79D2D428FA8CAD61661B16BB3" commented="no"><enum>(ii)</enum><text display-inline="yes-display-inline">20 weeks for fiscal year 2026;</text></clause><clause id="H51BC83FA3F7B4B5F9D031C35E0B2A363" commented="no"><enum>(iii)</enum><text>18 weeks for fiscal year 2027; and</text></clause><clause id="H24462ECFC2C54C508AE5A8B6E82C248F" commented="no"><enum>(iv)</enum><text>16 weeks for fiscal year 2028.</text></clause></subparagraph><subparagraph id="HCA23F858460B4D3B86D99F4EB9E409A2" commented="no"><enum>(D)</enum><header>Publication</header><text display-inline="yes-display-inline">If an adjustment to the operating reserve is made under this paragraph, the Secretary shall publish in the Federal Register notice under paragraph (1) the rationale for the amount of the adjustment and the supporting methodologies.</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H5D668870931C4966B530099D8FF65933"><enum>(d)</enum><header>Exemption from fees</header><text display-inline="yes-display-inline">Section 740(d)(4) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-12">21 U.S.C. 379j–12(d)(4)</external-xref>) is amended to read as follows: </text><quoted-block style="OLC" id="H3A934ED5A5E04EBAB3E3DAC0F460CDB9" display-inline="no-display-inline"><paragraph id="HEF568355DC77487C9A93FEC089505DDA"><enum>(4)</enum><header>Exemption from fees</header><text display-inline="yes-display-inline">Fees under paragraphs (2), (3), and (4) of subsection (a) shall not apply with respect to any person who is the named applicant or sponsor of an animal drug application, supplemental animal drug application, or investigational animal drug submission if such application or submission involves the intentional genomic alteration of an animal that is intended to produce a drug, device, or biological product subject to fees under section 736, 738, 744B, or 744H.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H73DD269BA7CE4F80A3F073C80A1886ED"><enum>(e)</enum><header>Crediting and availability of fees</header><paragraph id="H4D304043DF974A76A06D5DDD4649FC27"><enum>(1)</enum><header>Authorization of appropriations</header><text display-inline="yes-display-inline">Section 740(g)(3) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-12">21 U.S.C. 379j–12(g)(3)</external-xref>) is amended by striking <quote>2019 through 2023</quote> and inserting <quote>2024 through 2028</quote>.</text></paragraph><paragraph id="HA0127F99DA0748B390992E8BA5FDE43B"><enum>(2)</enum><header>Collection shortfalls</header><text display-inline="yes-display-inline">Section 740(g) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-12">21 U.S.C. 379j–12(g)</external-xref>) is amended—</text><subparagraph id="H32F0B917F6FE4808A24B6F7A69414789"><enum>(A)</enum><text>in paragraph (3), by striking <quote>and paragraph (5)</quote>; and </text></subparagraph><subparagraph id="H16D84A25FF0241528B623BA468F6A389"><enum>(B)</enum><text>by striking paragraph (5).</text></subparagraph></paragraph></subsection></section><section id="HC11CA5D390A9483A9B91F963028D3A1B"><enum>104.</enum><header>Reauthorization; reporting requirements</header><text display-inline="no-display-inline">Section 740A of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-13">21 U.S.C. 379j–13</external-xref>) is amended—</text><paragraph id="H9F7BC3ED692247AAA0F4B7BF1D7FB585"><enum>(1)</enum><text display-inline="yes-display-inline">in subsection (a), by striking <quote>2018</quote> and inserting <quote>2023</quote>;</text></paragraph><paragraph id="HCB3645BBD78E4E5FACEBD268754AD8E2"><enum>(2)</enum><text display-inline="yes-display-inline">by striking <quote>2019</quote> each place it appears in subsections (a) and (b) and inserting <quote>2024</quote>; and</text></paragraph><paragraph id="H0FA17BB1A2FF4D7E8C51B8687FA9ADAA"><enum>(3)</enum><text>in subsection (d)—</text><subparagraph id="H17F40B8876FE4E7FBCD3B3C10A6DD343"><enum>(A)</enum><text>in paragraph (1), by striking <quote>2023</quote> and inserting <quote>2028</quote>; and</text></subparagraph><subparagraph id="HE0F89D92CEDB40EF85EFB703E8917F1E"><enum>(B)</enum><text>in paragraph (5), by striking <quote>2023</quote> and inserting <quote>2028</quote>. </text></subparagraph></paragraph></section><section id="HCF74E576ECBE4EE58A5E9D7B2CD34772"><enum>105.</enum><header>Savings clause</header><text display-inline="no-display-inline">Notwithstanding the amendments made by this title, part 4 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-11">21 U.S.C. 379j–11 et seq.</external-xref>), as in effect on the day before the date of enactment of this title, shall continue to be in effect with respect to animal drug applications and supplemental animal drug applications (as defined in such part as of such day) that on or after October 1, 2018, but before October 1, 2023, were accepted by the Food and Drug Administration for filing with respect to assessing and collecting any fee required by such part for a fiscal year prior to fiscal year 2024.</text></section><section id="H05348EF5DEFB4E0880EF39F3A55DE111"><enum>106.</enum><header>Effective date</header><text display-inline="no-display-inline">The amendments made by this title shall take effect on October 1, 2023, or the date of the enactment of this Act, whichever is later, except that fees under part 4 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-11">21 U.S.C. 379j–11 et seq.</external-xref>), as amended by this title, shall be assessed for animal drug applications and supplemental animal drug applications received on or after October 1, 2023, regardless of the date of the enactment of this Act.</text></section><section id="H81D18433033948A2967F7FB86988C157"><enum>107.</enum><header>Sunset dates</header><subsection id="HECF2AEFC3883435FBA556FB407D75686"><enum>(a)</enum><header>Authorization</header><text display-inline="yes-display-inline">Sections 739 and 740 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. <external-xref legal-doc="usc" parsable-cite="usc/21/379j-11">21 U.S.C. 379j–11</external-xref>; 379j–12) shall cease to be effective October 1, 2028.</text></subsection><subsection id="H28B977A47FAC44F392E03B9F50CBE392"><enum>(b)</enum><header>Reporting requirements</header><text>Section 740A of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-13">21 U.S.C. 379j–13</external-xref>) shall cease to be effective January 31, 2029.</text></subsection><subsection id="H6782E5CEFE734E0BADD67B49FB9A5609"><enum>(c)</enum><header>Previous sunset provision</header><text display-inline="yes-display-inline">Effective October 1, 2023, subsections (a) and (b) of section 107 of the Animal Drug User Fee Amendments of 2018 (<external-xref legal-doc="public-law" parsable-cite="pl/115/234">Public Law 115–234</external-xref>) are repealed.</text></subsection></section></title><title id="H1DCACC2CFAB64FB8943A6A41CCEFEA6D" style="OLC"><enum>II</enum><header>Fees Relating to Generic Animal Drugs</header><section id="HCA9A0A77A8FF48808C7FE6F06E7C3379"><enum>201.</enum><header>Short title; finding</header><subsection id="HE0E93200AD794A918F721EDF47D13E09"><enum>(a)</enum><header>Short title</header><text>This title may be cited as the <quote><short-title>Animal Generic Drug User Fee Amendments of 2023</short-title></quote>.</text></subsection><subsection id="H9B08A210914040DABF3CB50F73259394"><enum>(b)</enum><header>Finding</header><text display-inline="yes-display-inline">Congress finds that the fees authorized by the amendments made in this title will be dedicated toward expediting the generic new animal drug development process and the review of abbreviated applications for generic new animal drugs, supplemental abbreviated applications for generic new animal drugs, and investigational submissions for generic new animal drugs as set forth in the goals identified for purposes of part 5 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-21">21 U.S.C. 379j–21 et seq.</external-xref>), in the letters from the Secretary of Health and Human Services to the Chairman of the Committee on Energy and Commerce of the House of Representatives and the Chairman of the Committee on Health, Education, Labor and Pensions of the Senate as set forth in the Congressional Record.</text></subsection></section><section id="H757D356F8C0043D3A6BC215526304001"><enum>202.</enum><header>Authority to assess and use generic new animal drug fees</header><subsection id="H0330E9364563403DA763A6F931391384"><enum>(a)</enum><header>Generic Investigational New Animal Drug File Fee</header><text display-inline="yes-display-inline">Section 741(a) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-21">21 U.S.C. 379j–21(a)</external-xref>) is amended by adding at the end the following:</text><quoted-block style="OLC" id="HC55EE8681A0C4C64B07DC2EEFC8D4DF7" display-inline="no-display-inline"><paragraph id="H96A01F816BD44124B8763DF91456E567" commented="no"><enum>(4)</enum><header>Generic investigational new animal drug file fee</header><subparagraph id="HE93DA323E8F9470F865BFD97BF839E09" commented="no"><enum>(A)</enum><header>In general</header><clause id="H270C862E91D14DE3A0054255A3682DDF"><enum>(i)</enum><header>New file request</header><text>Each person that submits a request to establish a generic investigational new animal drug file on or after October 1, 2023, shall be assessed a fee as established under subsection (c).</text></clause><clause id="H826F08348E0D4CF793EFD8CD36D0B7BA" commented="no"><enum>(ii)</enum><header>New submission to established file</header><text display-inline="yes-display-inline">Each person that makes a submission to a generic investigational new animal drug file on or after October 1, 2023, where such file was established prior to October 1, 2023, shall be assessed a fee for the first submission on or after October 1, 2023, as established under subsection (c).</text></clause></subparagraph><subparagraph id="HCDC624D7E9054D6887718D477870C44C" commented="no"><enum>(B)</enum><header>Payment</header><clause id="H0EFC6D459EBD4A4383CB5437BD3E7511"><enum>(i)</enum><header>New file request</header><text>The fee required by subparagraph (A)(i) shall be due upon submission of the request to establish the generic investigational new animal drug file.</text></clause><clause id="H715EE9E1D0E94521830684659D251546"><enum>(ii)</enum><header>New submission to established file</header><text>The fee required by subparagraph (A)(ii) shall be due upon the first submission to the generic investigational new animal drug file.</text></clause></subparagraph><subparagraph id="HC4F3F58E912943F6991A86251A440998" commented="no"><enum>(C)</enum><header>Exceptions</header><clause id="HE7BB4BE89C954D08B72FB114B04AA79E" commented="no"><enum>(i)</enum><header>Terminating an existing generic investigational new animal drug file</header><text display-inline="yes-display-inline">If a person makes a submission to the generic investigational new animal drug file to terminate that file, the person shall not be subject to a fee under subparagraph (A)(ii) for that submission.</text></clause><clause id="H41BDDFE335AD43CCB6CD5FA3A09E7C72" commented="no"><enum>(ii)</enum><header>Transferring an existing generic investigational new animal drug file</header><text display-inline="yes-display-inline">If a person makes a submission to the generic investigational new animal drug file to transfer that file to a different generic new animal drug sponsor, the person shall not be subject to a fee under subparagraph (A)(ii) for that submission.</text></clause></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="HEA09AF8BF24C4258A24F0C6F056032E5"><enum>(b)</enum><header>Fee revenue amounts</header><text display-inline="yes-display-inline">Section 741(b) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-21">21 U.S.C. 379j–21(b)</external-xref>) is amended—</text><paragraph id="HA91005D148A04E23BF9D496EEE3DF9F6"><enum>(1)</enum><text>in paragraph (1)—</text><subparagraph id="HC112AB8B8BD745F9AB14614F5D75A711"><enum>(A)</enum><text>by striking <quote>2019 through 2023</quote> and inserting <quote>2024 through 2028</quote>; and</text></subparagraph><subparagraph id="H73A1DCF47B4642D09BD918CF9A56F478"><enum>(B)</enum><text>by striking <quote>$18,336,340</quote> and inserting <quote>$25,000,000</quote>; and</text></subparagraph></paragraph><paragraph id="H891D9D1013CC4826BA20D2472982E868"><enum>(2)</enum><text>in paragraph (2)—</text><subparagraph id="H18FDE2F902A64AFDB88394A272D1600B"><enum>(A)</enum><text>in subparagraph (A)—</text><clause id="H0436F6BEBB984F47BE64781C4E301279"><enum>(i)</enum><text>by striking <quote>25 percent</quote> and inserting <quote>20 percent</quote>; and</text></clause><clause id="HD7E65F1583F3416A83A5F22F24DB3F84"><enum>(ii)</enum><text><italic></italic>by inserting before the semicolon at the end the following: <quote>and fees under subsection (a)(4) (relating to generic investigational new animal drug files)</quote>;</text></clause></subparagraph><subparagraph id="H5A5DFB2F8CC3497CA579125D4B42BAA5"><enum>(B)</enum><text>in subparagraph (B), by striking <quote>37.5 percent</quote> and inserting <quote>40 percent</quote>; and</text></subparagraph><subparagraph id="H7062A6B0E0DF4B4B8678723E999B0A1B"><enum>(C)</enum><text display-inline="yes-display-inline">in subparagraph (C), by striking <quote>37.5 percent</quote> and inserting <quote>40 percent</quote>. </text></subparagraph></paragraph></subsection><subsection id="H8ED52F309A1249FE81A3D771C03D4A98"><enum>(c)</enum><header>Annual fee setting; adjustments</header><paragraph id="HDB2F54487A644A3EB70E2730364F5FF2"><enum>(1)</enum><header>Annual fee setting</header><text display-inline="yes-display-inline"> Section 741(c)(1) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-21">21 U.S.C. 379j–21(c)(1)</external-xref>) is amended to read as follows: </text><quoted-block style="OLC" id="HC11AB055992B4CA2A05E2F8A053DC80C" display-inline="no-display-inline"><paragraph id="H25D02011B8CE4734B9FE3007ED87A9D8"><enum>(1)</enum><header>Annual fee setting</header><text display-inline="yes-display-inline">The Secretary shall establish, not later than 60 days before the start of each fiscal year beginning after September 30, 2023, for that fiscal year—</text><subparagraph id="H35E323EA6AE74E5287495522ABE38E23"><enum>(A)</enum><text display-inline="yes-display-inline">abbreviated application fees that are based on the revenue amounts established under subsection (b), the adjustments provided under this subsection, and the amount of fees anticipated to be collected under subsection (a)(4) during that fiscal year;</text></subparagraph><subparagraph id="H105413E96D9549328092335071E2FA3F"><enum>(B)</enum><text display-inline="yes-display-inline">generic new animal drug sponsor fees, and generic new animal drug product fees, based on the revenue amounts established under subsection (b) and the adjustments provided under this subsection; and</text></subparagraph><subparagraph id="HF3060A7B35A247648F825379A5E5F076"><enum>(C)</enum><text display-inline="yes-display-inline">a generic investigational new animal drug file fee of $50,000 for each request or submission described in subsection (a)(4)(A).</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph><paragraph id="H7F30CD5B6A474070B0537D09E9303578"><enum>(2)</enum><header>Inflation adjustment</header><text display-inline="yes-display-inline">Section 741(c)(2) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-21">21 U.S.C. 379j–21(c)(2)</external-xref>) is amended—</text><subparagraph id="HA6592844CEAB476F8FB18ED9013195C3"><enum>(A)</enum><text>in subparagraph (A)—</text><clause id="H4727E165C4FF40ABB60415B980CCC6EB"><enum>(i)</enum><text>in the matter preceding clause (i), by striking <quote>2020</quote> and inserting <quote>2025</quote>; and</text></clause><clause id="H3B066C63A16845ECA18E82A0835F08F2"><enum>(ii)</enum><text>in clause (iii), by striking <quote>Baltimore</quote> and inserting <quote>Arlington-Alexandria</quote>; and</text></clause></subparagraph><subparagraph id="H36C19E440989478C8CD4FE4CEA3C8467"><enum>(B)</enum><text display-inline="yes-display-inline">in subparagraph (B), by striking <quote>2020</quote> and inserting <quote>2025</quote>.</text></subparagraph></paragraph><paragraph id="HDAD8D7B3987E483984A63B510B845A0B"><enum>(3)</enum><header>Workload adjustment</header><text display-inline="yes-display-inline">Section 741(c)(3) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-21">21 U.S.C. 379j–21(c)(3)</external-xref>) is amended—</text><subparagraph id="HF6462FA5A15944C08E1F927F625E1916"><enum>(A)</enum><text>in subparagraph (A)—</text><clause id="HED12F4AD573545A59CFCF068F8A1BDD6"><enum>(i)</enum><text display-inline="yes-display-inline">in the matter preceding clause (i), by striking <quote>2020</quote> and inserting <quote>2025</quote>; </text></clause><clause id="H4D06D9A93DDE40149DAB97EC9FCDBD6F"><enum>(ii)</enum><text>in clause (i)—</text><subclause id="HA371038C00DA47CEAD474958DFD40635"><enum>(I)</enum><text>by striking <quote>and investigational generic new animal drug protocol submissions</quote> and inserting <quote>investigational generic new animal drug protocol submissions, requests to establish a generic investigational new animal drug file, and generic investigational new animal drug meeting requests</quote>; and</text></subclause><subclause id="HFB06967A48CC49CCB545ED4DC8EE85A8"><enum>(II)</enum><text>by striking <quote>; and</quote> and inserting a semicolon; </text></subclause></clause><clause id="HF16EB4F4CB9D40BA9E62D7A671091E52"><enum>(iii)</enum><text>by redesignating clause (ii) as clause (iii); and</text></clause><clause id="HC243F5D18AC94EC9A6E9B5F1FC0BEC9A"><enum>(iv)</enum><text>by inserting after clause (i) the following: </text><quoted-block style="OLC" id="HD5A1EAB14C1C442EBF36F6D4A2088527" display-inline="no-display-inline"><clause id="H7D10D36BF56643E2900D0DA41EEF18DD"><enum>(ii)</enum><text display-inline="yes-display-inline">if the workload adjustment calculated by the Secretary under clause (i) exceeds 25 percent, the Secretary shall use 25 percent for the adjustment; and</text></clause><after-quoted-block>; and</after-quoted-block></quoted-block></clause></subparagraph><subparagraph id="H1F527252494140B0A87822F3A16E0710"><enum>(B)</enum><text>in subparagraph (B), by striking <quote>2021 through 2023</quote> and inserting <quote>2026 through 2028</quote>.</text></subparagraph></paragraph><paragraph id="H0A78F17800004352B08FABBE28AD0652"><enum>(4)</enum><header>Final year adjustment</header><text display-inline="yes-display-inline">Section 741(c)(4) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-21">21 U.S.C. 379j–21(c)(4)</external-xref>) is amended—</text><subparagraph id="H4AE8E3A82AE346F49E83C51163D5B724"><enum>(A)</enum><text>by striking <quote>2023</quote> each place it appears and inserting <quote>2028</quote>; and</text></subparagraph><subparagraph id="H5B7F110A8331458692F1A1E0D6FE5F7E"><enum>(B)</enum><text>by striking <quote>2024</quote> and inserting <quote>2029</quote>.</text></subparagraph></paragraph></subsection><subsection id="HC36612FAFB2F4385BF588124F8A5FBF9"><enum>(d)</enum><header>Fee waiver or reduction; exemption from fees</header><text display-inline="yes-display-inline">Subsection (d) of section 741 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-21">21 U.S.C. 379j–21</external-xref>) is amended to read as follows:</text><quoted-block display-inline="no-display-inline" id="HD20E8547AE3B45A887F33B5C5FB595A4" style="OLC"><subsection id="H6D0BC1EC840A4EBEA3A49B421584395D"><enum>(d)</enum><header>Fee waiver or reduction</header><text display-inline="yes-display-inline">The Secretary shall grant a waiver from, or a reduction of, one or more fees assessed under subsection (a) where the Secretary finds that the generic new animal drug is intended solely to provide for a minor use or minor species indication.</text></subsection><after-quoted-block>.</after-quoted-block></quoted-block></subsection><subsection id="H4284E358634B4635A2D6D04E49494250"><enum>(e)</enum><header>Effect of failure To pay fees</header><text display-inline="yes-display-inline">Section 741(e) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-21">21 U.S.C. 379j–21(e)</external-xref>) is amended by striking <quote>The Secretary may discontinue</quote> and inserting <quote>A request to establish a generic investigational new animal drug file that is submitted by a person subject to fees under subsection (a) shall be considered incomplete and shall not be accepted for action by the Secretary until all fees owed by such person have been paid. The Secretary may discontinue</quote>.</text></subsection><subsection id="H92D105DCCC5149ACA5FCCDD7CDBA9D5F"><enum>(f)</enum><header>Assessment of fees</header><text display-inline="yes-display-inline">Section 741(f)(2) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-21">21 U.S.C. 379j–21(f)(2)</external-xref>) is amended by striking <quote>sponsors, and generic new animal drug products at any time</quote> and inserting <quote>products, generic new animal drug sponsors, and generic investigational new animal drug files at any time</quote>.</text></subsection><subsection id="H1B5C16A69D31431385172942D540FE91"><enum>(g)</enum><header>Crediting and availability of fees</header><text display-inline="yes-display-inline">Section 741(g) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-21">21 U.S.C. 379j–21(g)</external-xref>) is amended—</text><paragraph id="H6784C4FE860648CE93945201E0B79CE3"><enum>(1)</enum><text>in paragraph (3), by striking <quote>2019 through 2023</quote> and inserting <quote>2024 through 2028</quote>; </text></paragraph><paragraph id="HE944988AD73844F8A45A063C6B960A26"><enum>(2)</enum><text display-inline="yes-display-inline">by striking the second paragraph (4) (relating to Offset), as added by section 202 of the Animal Generic Drug User Fee Amendments of 2013 (<external-xref legal-doc="public-law" parsable-cite="pl/113/14">Public Law 113–14</external-xref>); and</text></paragraph><paragraph id="HA543627CF59C40CC9CA109BE96E9BC1B"><enum>(3)</enum><text>by adding at the end the following: </text><quoted-block style="OLC" id="HB51B6FF12F2B4D8B8B9CD2656A5E3A93" display-inline="no-display-inline"><paragraph id="H2462A74C86124480A7CB254BAA3F6DBE" commented="no"><enum>(5)</enum><header>Recovery of collection shortfalls</header><text display-inline="yes-display-inline"><italic></italic>The amount of fees otherwise authorized to be collected under this section shall be increased— </text><subparagraph id="H6C1CB110EC0745A79D9B9CE62AD29D62" commented="no"><enum>(A)</enum><text display-inline="yes-display-inline">for fiscal year 2026, by the amount, if any, by which the amount collected under this section and appropriated for fiscal year 2024 falls below the amount of fees authorized for fiscal year 2024 under paragraph (3);</text></subparagraph><subparagraph id="HC7EB201031AC40CBBAC1DC31360F97B7" commented="no"><enum>(B)</enum><text display-inline="yes-display-inline">for fiscal year 2027, by the amount, if any, by which the amount collected under this section and appropriated for fiscal year 2025 falls below the amount of fees authorized for fiscal year 2025 under paragraph (3); and</text></subparagraph><subparagraph id="HD02172EBC2C1443B98767CBD9A3D012F" commented="no"><enum>(C)</enum><text display-inline="yes-display-inline">for fiscal year 2028, by the amount, if any, by which the amount collected under this section and appropriated for fiscal years 2026 and 2027 (including estimated collections for fiscal year 2027) falls below the amount of fees authorized for such fiscal years under paragraph (3).</text></subparagraph></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection><subsection id="H48BD10BF511B4CEB8E2BBFFABFAA4ED5"><enum>(h)</enum><header>Definitions</header><text display-inline="yes-display-inline">Section 741(k) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-21">21 U.S.C. 379j–21(k)</external-xref>) is amended—</text><paragraph id="HE0B45408F6CF4EDAA77184345E957563"><enum>(1)</enum><text>by redesignating paragraphs (8), (9), (10), and (11) as paragraphs (9), (10), (11), and (13), respectively; </text></paragraph><paragraph id="HB1DAA0233A3846F89923F457EC77B69F"><enum>(2)</enum><text>by inserting after paragraph (7) the following: </text><quoted-block style="OLC" id="HA6564C94EAC94BDDAFD08E937124B533" display-inline="no-display-inline"><paragraph id="HD81020D6A49647EE90C9D5755A405203"><enum>(8)</enum><header>Generic investigational new animal drug meeting request</header><text display-inline="yes-display-inline">The term <quote>generic investigational new animal drug meeting request</quote> means a request submitted by a generic new animal drug sponsor to meet with the Secretary to discuss an investigational submission for a generic new animal drug.</text></paragraph><after-quoted-block>; </after-quoted-block></quoted-block></paragraph><paragraph id="H2338FA1772894DB1AFE84B835AD47863"><enum>(3)</enum><text display-inline="yes-display-inline">in paragraph (11) (as so redesignated), by adding at the end the following: </text><quoted-block style="OLC" id="H5DA3C58787954F8B889E066542EE7C8D" display-inline="no-display-inline"><subparagraph id="H3CBCC18CE76E4EF2B1ED611801674F9E"><enum>(I)</enum><text display-inline="yes-display-inline">The activities necessary for exploration and implementation of the United States and European Union Mutual Recognition Agreement for Pharmaceutical Good Manufacturing Practice Inspections, and the United States and United Kingdom Mutual Recognition Agreement Sectoral Annex for Pharmaceutical Good Manufacturing Practices, and other mutual recognition agreements<italic></italic>, with respect to generic new animal drug products subject to review, including implementation activities prior to and following product approval.</text></subparagraph><after-quoted-block>; and</after-quoted-block></quoted-block></paragraph><paragraph id="H3A8B1B0F8B3C4683B207E5E84EF3C4F8"><enum>(4)</enum><text>by inserting after paragraph (11) (as so redesignated) the following:</text><quoted-block style="OLC" id="HC88ECAC6FF524FCA8D5C5B9A66DF8120" display-inline="no-display-inline"><paragraph id="H9AB6EC4EB8544A81B6BCE0501495BB28"><enum>(12)</enum><header>Request to establish a generic investigational new animal drug file</header><text display-inline="yes-display-inline">The term <quote>request to establish a generic investigational new animal drug file</quote> means the submission to the Secretary of a request to establish a generic investigational new animal drug file to contain investigational submissions for a generic new animal drug.</text></paragraph><after-quoted-block>.</after-quoted-block></quoted-block></paragraph></subsection></section><section id="H2E56B76819BA436BBD1F2F2419B9503B"><enum>203.</enum><header>Reauthorization; reporting requirements</header><text display-inline="no-display-inline">Section 742 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-22">21 U.S.C. 379j–22</external-xref>) is amended—</text><paragraph id="H583CA0AC29A44DECA9B4B6A173DC6CB7"><enum>(1)</enum><text display-inline="yes-display-inline">in subsection (a), by striking <quote>2018</quote> and inserting <quote>2023</quote>;</text></paragraph><paragraph id="H9B5DA4E6B42E4B0EB926C24A66B32D5F"><enum>(2)</enum><text display-inline="yes-display-inline">by striking <quote>2019</quote> each place it appears in subsections (a) and (b) and inserting <quote>2024</quote>; and</text></paragraph><paragraph id="HAFB2F3A33CA54C558ABF9B172423176D"><enum>(3)</enum><text>in subsection (d), by striking <quote>2023</quote> each place it appears and inserting <quote>2028</quote>.</text></paragraph></section><section id="H1A76396576CD44CBA23BB789D7AA4F63"><enum>204.</enum><header>Savings clause</header><text display-inline="no-display-inline">Notwithstanding the amendments made by this title, part 5 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-21">21 U.S.C. 379j–21 et seq.</external-xref>), as in effect on the day before the date of enactment of this title, shall continue to be in effect with respect to abbreviated applications for a generic new animal drug and supplemental abbreviated applications for a generic new animal drug (as defined in such part as of such day) that on or after October 1, 2018, but before October 1, 2023, were accepted by the Food and Drug Administration for filing with respect to assessing and collecting any fee required by such part for a fiscal year prior to fiscal year 2024.</text></section><section id="H2B1DE415AAE543748C10DC0CF5BE0486"><enum>205.</enum><header>Effective date</header><text display-inline="no-display-inline">The amendments made by this title shall take effect on October 1, 2023, or the date of the enactment of this Act, whichever is later, except that fees under part 5 of subchapter C of chapter VII of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-21">21 U.S.C. 379j–21 et seq.</external-xref>), as amended by this title, shall be assessed for abbreviated applications for a generic new animal drug and supplemental abbreviated applications for a generic new animal drug received on or after October 1, 2023, regardless of the date of enactment of this Act.</text></section><section id="HAF76775DBD9845738378B6233DBDB3C2"><enum>206.</enum><header>Sunset dates</header><subsection id="HECD6F8FAA93848A98C3110319C2AA333"><enum>(a)</enum><header>Authorization</header><text display-inline="yes-display-inline">Section 741 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-21">21 U.S.C. 379j–21</external-xref>) shall cease to be effective October 1, 2028.</text></subsection><subsection id="H6E79ABF614E249C1851529AC17FF251B"><enum>(b)</enum><header>Reporting requirements</header><text>Section 742 of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-22">21 U.S.C. 379j–22</external-xref>) shall cease to be effective January 31, 2029.</text></subsection><subsection id="H57A03980F84644948BD07FE1FE18411B"><enum>(c)</enum><header>Previous sunset provision</header><text display-inline="yes-display-inline">Effective October 1, 2023, subsections (a) and (b) of section 206 of the Animal Generic Drug User Fee Amendments of 2018 (<external-xref legal-doc="public-law" parsable-cite="pl/115/234">Public Law 115–234</external-xref>) are repealed.</text></subsection></section></title><title id="HEC290649D102411FAE4C60904BFF0A31"><enum>III</enum><header>Supporting Animal and Human Health</header><section id="H789C154723164760A9706AE0BAEC21C8"><enum>301.</enum><header>Reporting requirements</header><text display-inline="no-display-inline">Section 740A of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/379j-13">21 U.S.C. 379j–13</external-xref>), as amended by section 104, is further amended—</text><paragraph id="H6FB783EA1FB4479FA55F70A1D42646AE"><enum>(1)</enum><text>in subsection (a)—</text><subparagraph id="HB851962EE64D418EBC150E8DF32B9213"><enum>(A)</enum><text>by striking <quote>Beginning with</quote> and inserting the following: </text><quoted-block style="OLC" id="H05F6406E79F74D60AEE3E5E4B7194D11" display-inline="no-display-inline"><paragraph id="HA9C7B9EB40DC4993BB48F648F6FF7439"><enum>(1)</enum><header>In general</header><text display-inline="yes-display-inline">Beginning with</text></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph><subparagraph id="HE3886BAC886B484B941B0D28D1349C09"><enum>(B)</enum><text>by adding at the end the following: </text><quoted-block style="OLC" id="H61B4D2935DA24E6CBB6C29B45C805EA3" display-inline="no-display-inline"><paragraph id="HDD50C311BDC1443F9289601C6FFFBDED"><enum>(2)</enum><header>Contents</header><text display-inline="yes-display-inline">The report under paragraph (1) shall include the following:</text><subparagraph id="H7567B9BA14D0496EABEBD7B343816CC0"><enum>(A)</enum><text display-inline="yes-display-inline">Data, analysis and discussion of the changes in the number of individuals hired and funded by fees collected pursuant to section 740, and data, analysis, and discussion of the number of full-time equivalents in the animal drug review program, including a breakdown by funding from fees collected pursuant to section 740 versus budget authority, and by each division within the Center for Veterinary Medicine, the Office of Regulatory Affairs, and the Office of the Commissioner.</text></subparagraph><subparagraph id="HE37B9E999AFE47B29C5F0FF59E2920F3"><enum>(B)</enum><text display-inline="yes-display-inline">Data, analysis, and discussion of the changes in the fee revenue amounts and costs for the process for the review of animal drug applications, including identifying—</text><clause id="HDE9085573D6A4A598DA8F7AF41CEF0B6"><enum>(i)</enum><text>the drivers of such changes; and </text></clause><clause id="H901BEB33A7FC4AB49D2810E8027F05FD"><enum>(ii)</enum><text>changes in the total cost per full-time equivalent in the animal drug review program.</text></clause></subparagraph><subparagraph id="H40A19B1AC09C4D72BB03D8E2335B2871"><enum>(C)</enum><text display-inline="yes-display-inline">Data, analysis, and discussion of changes in the average full-time equivalent hours required to complete review of each type of animal drug application.</text></subparagraph><subparagraph id="H2F0C9161266B41E5A509484113BD27E1"><enum>(D)</enum><text display-inline="yes-display-inline">For fiscal years 2024 and 2025<italic></italic>, of the meeting requests from animal drug sponsors for which the Secretary has determined that a face-to-face meeting is appropriate, the number of face-to-face meetings requested by sponsors to be conducted in person (in such manner as the Secretary shall prescribe on the website of the Food and Drug Administration), and the number of such in-person meetings granted by the Secretary.</text></subparagraph></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph></paragraph><paragraph id="HE2A02878B4804F319C56D6C2BD990EE9"><enum>(2)</enum><text>in subsection (d)—</text><subparagraph id="HF82EF686CBDF4C4A91FF29EDEAAF6E82"><enum>(A)</enum><text>in paragraph (5), by inserting a comma after <quote>paragraph (4)</quote>; </text></subparagraph><subparagraph id="H13FB15E2AE0E4396B2E58623C48A54B0"><enum>(B)</enum><text>by redesignating paragraph (6) as paragraph (7);</text></subparagraph><subparagraph id="H44114034E3384973A0232C01FD27778F"><enum>(C)</enum><text>by inserting after paragraph (5) the following: </text><quoted-block style="OLC" id="HFA71B640A54C49999BEA180C471C73CA" display-inline="no-display-inline"><paragraph id="H282CE1BB11574076B84928B2A5B2D617"><enum>(6)</enum><header>Updates to Congress</header><text display-inline="yes-display-inline">The Secretary, in consultation with regulated industry, shall provide regular updates on negotiations on the reauthorization of this part to the Committee on Health, Education, Labor, and Pensions of the Senate and the Committee on Energy and Commerce of the House of Representatives.</text></paragraph><after-quoted-block>; and</after-quoted-block></quoted-block></subparagraph><subparagraph id="H78EA963DA1A145EB92DAD77CA7AA37D9"><enum>(D)</enum><text>in paragraph (7) (as so redesignated)—</text><clause id="H49B2357DF9C24373BFC3CB635D0535B8"><enum>(i)</enum><text>in subparagraph (A)—</text><subclause id="H02F3EDEE21C640D8AF8B09DCDA0385E4"><enum>(I)</enum><text>by striking <quote>Before presenting the recommendations developed under paragraphs (1) through (5) to Congress, the Secretary</quote> and inserting <quote>The Secretary</quote>; and</text></subclause><subclause id="H060164D2C8904207B364300EC3730C44"><enum>(II)</enum><text>by inserting before the period at the end the following: <quote>, not later than 30 days after each such negotiation meeting</quote>; and</text></subclause></clause><clause id="H340C76860E8443ABA73528BEE093CFED"><enum>(ii)</enum><text>in subparagraph (B), by inserting <quote>, in sufficient detail, </quote> after <quote>shall summarize</quote>.</text></clause></subparagraph></paragraph></section><section id="H850F4732AEBF43B8B53D72ED2EAC3401"><enum>302.</enum><header>Definition of major species</header><text display-inline="no-display-inline">Section 201(nn) of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/321">21 U.S.C. 321(nn)</external-xref>) is amended by inserting <quote>, or remove species from,</quote> after <quote>add species to</quote>.</text></section><section id="H2F4EC2C7237A4E80A1463C864D8F4753"><enum>303.</enum><header>Antimicrobial resistance</header><subsection id="HA0DB1CDFD3E5474594793F7DE155487F"><enum>(a)</enum><header>Report on Antimicrobial Stewardship</header><text display-inline="yes-display-inline">Not later than December 31, 2023, the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report describing—</text><paragraph id="H226E555A73604518B7B8C99F5690814C"><enum>(1)</enum><text>activities conducted by the Center for Veterinary Medicine of the Food and Drug Administration (referred to in this section as <quote>the Center</quote>) during the period of fiscal years 2019 through 2023 to support antimicrobial stewardship in veterinary settings, including ongoing activities and the targeted completion date of such activities; and</text></paragraph><paragraph id="HB5D2204DFD344B56974462B23FC39027"><enum>(2)</enum><text display-inline="yes-display-inline">with respect to antimicrobial stewardship in veterinary settings—</text><subparagraph id="H3C823BC4D3C145B7B05C5CAAF012B77E"><enum>(A)</enum><text>the goals of the Center regarding supporting antimicrobial stewardship in veterinary settings; </text></subparagraph><subparagraph id="H9CDB8BDEB9C4468F98505537C05C06B0"><enum>(B)</enum><text>activities the Center plans to execute during the period of fiscal years 2024 through 2028 to support such goals, including targeted completion dates for such activities; and</text></subparagraph><subparagraph id="HCC41F47E53A64AF0A6113C34B1873CAB"><enum>(C)</enum><text>metrics the Center plans to use to evaluate progress toward its goals regarding supporting antimicrobial stewardship in veterinary settings.</text></subparagraph></paragraph></subsection><subsection id="HE063569E8F2B4B71BB7FDE2FD8E3BC21"><enum>(b)</enum><header>Annual progress reports</header><text display-inline="yes-display-inline">Not later than 120 days after the end of each fiscal year during which fees are collected under section 740, the Secretary shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report that includes—</text><paragraph id="H51C282C41DF64109B0EA660DB4EDCF3F"><enum>(1)</enum><text>a description of activities conducted by the Center in the prior fiscal year to support antimicrobial stewardship in veterinary settings, including progress made toward goals and activities specified in subsection (a)(2); </text></paragraph><paragraph id="HCA6E712ADE15466B88BC63BB018618EB"><enum>(2)</enum><text>in the case of an incomplete activity described in subsection (a)(2)(B) for which the target completion date has passed—</text><subparagraph id="H807D07DFE7F44CE38C23DF2AD65AE3F3"><enum>(A)</enum><text>an explanation for why such target completion date was not met; and</text></subparagraph><subparagraph id="H7529CCE3FA2E4F048185FD5314C303B0"><enum>(B)</enum><text>if applicable, the updated expected completion date for such activity;</text></subparagraph></paragraph><paragraph id="HFF47A05DC7E84B4882C537AEAB6FA660"><enum>(3)</enum><text>a description of emerging challenges related to antimicrobial stewardship in veterinary settings that impact Center activities; and</text></paragraph><paragraph id="H6FD81C61894D4EA1B72D9D7263AD3B01"><enum>(4)</enum><text>a description of activities undertaken to incentivize the development of new drugs for the treatment, prevention, or control of bacterial diseases in animals.</text></paragraph></subsection></section></title></legis-body><attestation><attestation-group><attestation-date date="20230717" chamber="House">Passed the House of Representatives July 17, 2023.</attestation-date><attestor display="yes">Kevin F. McCumber,</attestor><role>Clerk.</role></attestation-group></attestation><endorsement display="yes"><action-date>September 20, 2023</action-date><action-desc>Read twice and placed on the calendar</action-desc></endorsement></bill> 

